Study about correlation of anti-neutrophil cytoplasmic antibodies and anticardiolipin antibodies with thromboangiitis obliterans

被引:12
|
作者
Guo, Yi [1 ]
Dai, Yuanbin [1 ]
Lai, Junyu [2 ]
Fan, Ying [3 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Vasc Surg, Chongqing 400016, Peoples R China
[2] People Hosp Luzhou, Dept Gen Surg, Luzhou, Peoples R China
[3] Second People Hosp Yibin, Dept Gen Surg, Yibin, Sichuan, Peoples R China
关键词
Anti-neutrophil cytoplasmic antibodies (ANCA); anticardiolipid antibodies (ACA); thromboangiitis obliterans (TAO); THROMBOSIS; DISEASE; PATHOGENESIS; RISK; ANCA;
D O I
10.1177/1708538113478742
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Doctors often have difficulties in clinical diagnosis and clinical stage of thromboangiitis obliterans (TAO). Immunolesion was important in the initiation and progression of various kinds of vasculitis diseases, including TAO. Several kinds of immune complexes were developed by immunolesion, including anti-neutrophil cytoplasmic antibodies (ANCA) and anticardiolipin antibodies (ACA). Our aim was to determine if it is an effective way for clinical diagnosis and clinical stage of TAO by detection of the presence of ANCA and ACA in blood serum of patients with TAO and the relationship among the presence of ANCA, ACA and patients with different grades of TAO. Blood samples and clinical characteristics were collected from 38 patients with Rutherford grade I TAO, 30 patients with Rutherford grade II-III TAO, 75 patients with arteriosclerosis obliterans (ASO) and 65 healthy volunteers. Their serum samples were investigated for ANCA by indirect immunofluorescent (IIF), and for ACA and ANCA specificity antigens including reactivity to proteinase 3(PR3), myeloperoxidase (MPO), cathepsin G (CG), bactericidal/permesbility-increasing protein (BPI), elastase (HLE) and lactoferrin (LF) by enzyme linked immunosorbent assay (ELISA). (1) ANCA positive rate and titre were much higher in cases with Rutherford grade I TAO (52.6%, 20/38, 0.386 +/- 0.458) and Rutherford grade II-III TAO (73.3%, 22/30, 0.847 +/- 0.658) than those in cases with ASO (4%, 3/75, 0.011 +/- 0.002) and healthy volunteers (0%,0/65, 0.010 +/- 0.002) (P < 0.01). ANCA positive rate and titre were higher in cases with Rutherford grade II-III TAO (73.3%, 22/30, 0.847 +/- 0.658) than those in cases with Rutherford grade I TAO (52.6%, 20/38, 0.386 +/- 0.458) (P < 0.05). (2) ACA concentration was much higher in cases with Rutherford grade I TAO (270.13 +/- 13.05 IU/mL) and Rutherford grade II-III TAO (279.33 +/- 19.98 IU/mL) than that in cases with ASO (236.85 +/- 17.32 IU/mL) and healthy volunteers (229.16 +/- 15.55 IU/mL) (P < 0.05) respectively. (3) In 42 cases of ANCA-positive samples, there were 20 cases reacted with MPO, 14 cases reacted with LF, five cases reacted with HLE, five cases reacted with BPI and no one reacted with PR3 and CG. All cases were Rutherford grade II-III TAO. Our results indicate that ANCA, ANCA specificity antigens and ACA were detected susceptibly and availably in patients with TAO. Thus, detection of ANCA, ANCA specificity antigens and ACA was helpful for clinical diagnosis of TAO and detection of ANCA and ANCA specificity antigens was helpful for clinical staging of TAO. They are important assistance for clinical diagnosis and stage of TAO.
引用
收藏
页码:363 / 368
页数:6
相关论文
共 50 条
  • [11] Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides
    Csernok, E
    AUTOIMMUNITY REVIEWS, 2003, 2 (03) : 158 - 164
  • [12] Ectopic Relapse of Anti-neutrophil Cytoplasmic Antibody-associated Pituitary Vasculitis with No Elevation of Anti-neutrophil Cytoplasmic Antibodies after Renal Remission
    Muto, Reiko
    Inagaki, Koji
    Sato, Naokazu
    Sameshima, Tetsuro
    Nagakura, Yuka
    Baba, Satoshi
    Kato, Noritoshi
    Maruyama, Shoichi
    Akahori, Toshiyuki
    INTERNAL MEDICINE, 2020, 59 (24) : 3187 - 3193
  • [13] Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA)
    Talor, M. V.
    Stone, J. H.
    Stebbing, J.
    Barin, J.
    Rose, N. R.
    Burek, C. L.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 150 (01) : 42 - 48
  • [14] Antiphospholipid antibodies in thromboangiitis obliterans
    Maslowski, L
    McBane, R
    Alexewicz, P
    Wysokinski, WE
    VASCULAR MEDICINE, 2002, 7 (04) : 259 - 264
  • [15] Prevalence of anti-neutrophil cytoplasmic antibodies (ANCA) in juvenile chronic arthritis
    Speckmaier, M
    Rother, E
    Terreri, T
    Reiff, A
    Metzger, D
    Schuchmann, L
    Forster, J
    Peter, HH
    Brandis, M
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1996, 14 (02) : 211 - 216
  • [16] Atypical, cytoplasmic and perinuclear anti-neutrophil cytoplasmic antibodies in patients with inflammatory bowel disease
    Frenzer, A
    Fierz, W
    Rundler, E
    Hammer, B
    Binek, J
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 (09) : 950 - 954
  • [17] Anti-neutrophil cytoplasmic antibodies associated interstitial pneumonia: A possible new clinical entity
    Iannone, Claudia
    Pellico, Maria Rosa
    Caminati, Antonella
    Zompatori, Maurizio
    Tescaro, Lisa
    Luisi, Francesca
    Elia, Davide
    Mirenda, Maria Rosa
    Colleoni, Matteo
    Cassandro, Roberto
    Harari, Sergio
    Caporali, Roberto Felice
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2025,
  • [18] Clinical characteristics and outcome of double-seropositive patients with anti-glomerular basement membrane antibodies and anti-neutrophil cytoplasmic antibodies
    Ge, Yifei
    Zhu, Jinxing
    Yang, Guang
    Liu, Kang
    Yu, Xiangbao
    Sun, Bin
    Zhang, Bo
    Yuan, Yanggang
    Zeng, Ming
    Wang, Ningning
    Xing, Changying
    Mao, Huijuan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 138
  • [19] Anti-neutrophil cytoplasmic antibodies in the diagnosis of ulcerative colitis and Crohn's disease
    Gisbert, JP
    Luna, M
    Legido, J
    Hermida, C
    Maté, J
    Pajares, JM
    MEDICINA CLINICA, 2004, 122 (04): : 134 - 135
  • [20] Periaortitis Associated with Anti-neutrophil Cytoplasmic Antibodies Induced by Bevacizumab Combination Therapy
    Murakami, Shuji
    Saito, Haruhiro
    Ohe, Miki
    Kondo, Tetsuro
    Oshita, Fumihiro
    Yamada, Kouzo
    INTERNAL MEDICINE, 2013, 52 (05) : 589 - 591